3,000 RA patients to donate blood for future breakthroughs
NCT ID NCT04899895
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is building a large collection of blood samples from 3,000 people with rheumatoid arthritis. Researchers will use these samples to look for biomarkers that could help predict disease activity or treatment side effects. Participants must already be in a registry and starting a new medication. No test results are returned to participants or their doctors.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this biorepository could help researchers discover biomarkers to better understand rheumatoid arthritis and predict disease activity or treatment risks.
- What could go wrong
- This is an observational study, not a treatment trial. It collects samples for future research, so there is no direct benefit to participants, and the findings may take years to emerge.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2021
- Expected to finish
-
Dec 2100
An estimate. End dates often move.
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The following eligibility criteria are designed to select patients for whom study assessments are deemed appropriate. Patients must have attained at least the locally recognized age of consent and provide written or electronic informed consent to participate
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
A patient must satisfy all of the following criteria to be eligible for enrollment in the Biorepository study .1)Patient is currently participating in a Registry or is eligible to participate and enrolls in a Registry prior to enrollment in the Biorepository study. 2)Patient is starting an Eligible Medication\*with no prior exposure to the specific medication being prescribed. 3)Patient is able to complete Sample collection within fourteen (14) days prior to receiving thefirst dose of the Eligible Medication.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lupus are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Corrona, LLC
Waltham, Massachusetts, 02451, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Scientists probe why rheumatic pain feels different for everyone
- Custom knee guides put to the test in obese patients
- A new ankle? researchers track 400 people with an implant meant to restore movement
- Can a Job-Focused rehab program keep arthritis patients employed?
- Can an oral drug calm psoriatic arthritis? phase 3 trial puts deucravacitinib to the test